Study		Exclusion reasons	Remarks	Reference(s)
CheckMate 511, 2019	randomized controlled trial		phase IIIb/IV
Hersh, 2011	-	inadequate or absent control group		Hersh Invest New Drugs 2011; 29:489-98 10.1007/s10637-009-9376-8
Long, 2018	-	not relevant study design		Long Lancet Oncol. 2018; 19:672-681 10.1016/S1470-2045(18)30139-6
Lebbé, 2019	-	not relevant outcome		Lebbé J. Clin. Oncol. 2019; 37:867-875 10.1200/JCO.18.01998